Business Wire

MA-WATERS-CORPORATION

22.3.2022 13:02:10 CET | Business Wire | Press release

Share
Waters Introduces Faster, Reliable and Automated Solution for Mass and Purity Analysis of Biomolecules

Waters Corporation (NYSE:WAT) today introduced new software and analytical columns to aid biomolecule drug discovery and development. The new Waters™ Intact Mass app on waters_connect™ allows scientists using the BioAccord™ LC-MS System to confirm the mass of biomolecules and impurities made by synthetic or recombinant processes nearly twice as fast as other commercially available options.i

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005136/en/

“Acquiring mass and purity data of biomolecules is time consuming. Skilled analysis of complex mass spectrometry data is required, typically in remote specialist analytical laboratories,” said Jon Pratt, Waters Division Senior Vice President, Waters Corporation. “The new Waters Intact Mass App enables bioengineers and biochemists to accelerate drug discovery and development with simplified technology to generate mass confirmation data on their own in minutes/hours instead of days/weeks.”

Intact mass analysis is routinely performed during all stages of the development of biological drugs including proteins, peptides, oligonucleotide therapies and conjugates. In early stages of drug discovery, biochemists must analyze hundreds or even thousands of different samples per week. To help speed this process, the Waters Intact Mass app provides a fast, reliable, and automated solution to facilitate mass confirmation and purity determination of novel biotherapeutics. The application features intelligent automated deconvolution to process sample results within minutes of their capture, with minimal user input.

Introducing Waters MaxPeak Premier Protein BEH C4 300Å Columns for Intact & Subunit Protein Analyses

Complementing the introduction of the Intact Mass app is a new line of analytical columns that are essential for analyzing intact biomolecules and their subunits. The ACQUITY™ Premier and XBridge™ Premier Protein BEH C4 300Å Columns for the BioAccord LC-MS System feature MaxPeak High Performance Surfaces (HPS) technology that prevents the loss of sample analytes due to adsorption of phosphorylated and carboxylated molecules between the sample and metal surfaces of both the LC system and column. This enables up to 3X greater sensitivity for low-level intact mass analysis and 2X greater sensitivity for the intact mass analysis of phosphorylated proteins and low-level subunits of monoclonal antibodies.ii

The Intact Mass App on waters_connect is available for new BioAccord LC-MS Systems and as an upgrade to previously installed systems. MaxPeak Premier Protein BEH C4 300Å Columns are now available from Waters worldwide.

Additional Resources

About Waters Corporation (www.waters.com )

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, BioAccord, ACQUITY, Premier, UPLC, XBridge, MaxPeak, and waters_connect are trademarks of Waters Corporation.

_____________________
i Estimate based on obtaining the results for 96 samples using a Waters BioAccord System and Intact Mass parallel acquisition and processing approach as compared to the “acquire then process” workflow of commercially available offerings.

ii Based on a comparison of MaxPeak Premier Protein BEH C4 300Å Columns with stainless steel ACQUITY Protein 300Å Columns

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press release

This is the fourth quantum computer deployed by IQM to customers in Finland to boost research and education in a growing ecosystem. The system named Aalto Q20 quantum computer is online at Aalto University and will enable students and scientists a unique first-hand access to a world-class quantum computer. The university will use the quantum computer to perform scientific experiments on advanced level and to support national and European quantum research activities. IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum compute

Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press release

Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissionsBespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resiliencePartnership aligns with the science-based climate commitments of both companies Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multi

NTT DATA Unveils NVIDIA-Powered Enterprise AI Factories to Support Secure AI Adoption and Help Clients Drive Measurable ROI11.3.2026 11:00:00 CET | Press release

NTT DATA drives success in healthcare, manufacturing and other sectors with NVIDIA-powered technologies NTT DATA AI solutions now integrate NVIDIA AI Enterprise software, including NVIDIA NeMo and NIM Microservices to create a full-stack, production-ready, GPU-accelerated agentic AI platform NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI. NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to en

Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health11.3.2026 10:00:00 CET | Press release

£65m investment in new oral health manufacturing plant in Shanghai to support growth in the world’s largest gum health market Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 - including its fastest growing cities – reaching aspirational shoppers in-store and online Custom designed taste, foamier sensation and premium packaging to appeal to local consumers Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202

Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 09:00:00 CET | Press release

Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye